Trial Search Results

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Hoffmann-La Roche

Stanford Investigator(s):

Intervention(s):

  • Drug: Lampalizumab
  • Other: Sham Comparator

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Participants aged greater than or equal to (>/=) 50 years

   - Well demarcated area(s) of Geographic Atrophy (GA) secondary to Age-Related Macular
   Degeneration (AMD) with no evidence of prior or active choroidal neovascularization
   (CNV) in both eyes

Exclusion Criteria:

Ocular Exclusion Criteria (Study Eye):

   - History of vitrectomy surgery, submacular surgery, or other surgical intervention for
   AMD

   - Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein
   occlusion, and proliferative diabetic retinopathy

   - Previous intravitreal drug delivery (e.g., intravitreal corticosteroid injection,
   anti-angiogenic drugs, anti-complement agents, or device implantation)

Ocular Exclusion Criteria (Both Eyes):

   - GA in either eye due to causes other than AMD

   - Previous treatment with eculizumab, lampalizumab, and/or fenretinide

Ages Eligible for Study

50 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting